The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …

Exosomes are nanoscale vesicles secreted by most cells and have a phospholipid bilayer
structure. Exosomes contain DNA, small RNA, proteins, and other substances that can carry …

CD20 located predominantly on the B cells plays a crucial role in their development,
differentiation, and activation, and serves as a key therapeutic target for the treatment of B …

Diffuse large B‐cell lymphoma (DLBCL) is characterized by extensive genetic heterogeneity,
and this results in unpredictable responses to the current treatment, R‐CHOP, which …

Tumors accumulate high levels of mutant p53 (mutp53), which contributes to mutp53 gain-of-
function properties. The mechanisms that underlie such excessive accumulation are not fully …

Oncogenic MYC activation promotes proliferation in Burkitt lymphoma, but also induces cell-
cycle arrest and apoptosis mediated by p53, a tumor suppressor that is mutated in 40% of …

Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma associated with MYC
translocation. Here, we describe drug response profiling of 42 blood cancer cell lines …

Myxoid liposarcomas (MLS), malignant tumors of adipocyte origin, are driven by the FUS‐
DDIT 3 fusion gene encoding an aberrant transcription factor. The mechanisms whereby …

Purpose: One third of patients with diffuse large B-cell lymphoma (DLBCL) succumb to the
disease partly due to rituximab resistance. Rituximab-induced calcium flux is an important …

Anti‐CD20 monoclonal antibodies such as Rituximab, Ofatumumab, and Obinutuzumab are
widely used to treat lymphomas and autoimmune diseases. They act by depleting B cells …